轩竹生物-B(02575.HK)：就建议实施H股全流通向中国证监会备案

Core Viewpoint - Xuan Zhu Bio-B (02575.HK) has submitted a filing to the China Securities Regulatory Commission (CSRC) for the proposed implementation of full circulation of H-shares, converting approximately 357 million unlisted shares into H-shares on a one-to-one basis [1] Group 1 - The company plans to convert approximately 357 million unlisted shares into H-shares, which will then be listed and traded on the Hong Kong Stock Exchange [1] - The conversion is subject to the completion of all filing requirements, including obtaining necessary approvals from the CSRC and the Stock Exchange [1] - The proposed conversion aims to enhance liquidity and marketability of the company's shares [1]